<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94095">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910155</url>
  </required_header>
  <id_info>
    <org_study_id>71205502</org_study_id>
    <nct_id>NCT01910155</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspension (Par) Compared to CIPRODEX® (Ciprofloxacin 0.3%/Dexamethasone 0.1%) Sterile Otic Suspension (Alcon) in the Treatment of Adults With Acute Bacterial Otitis Externa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novum Pharmaceutical Research Services</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative efficacy and safety of the test
      formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par
      Pharmaceutical Companies, Inc.) to the already-marketed formulation CIPRODEX® (ciprofloxacin
      0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial
      otitis externa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Day 14-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the difference between the proportions of patients considered a clinical success at the End of Study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of Symptoms</measure>
    <time_frame>Day 14-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to complete resolution of disease specific clinically meaningful signs and symptoms at enrollment and the absence of new symptoms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Otitis Externa</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofloxacin/Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprodex (R)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin/Dexamethasone</intervention_name>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprodex (R)</intervention_name>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non lactating females 18-65 years of age inclusive.

          2. Signed informed consent form, which meets all of the criteria of current FDA
             regulations.

          3. If female and of child bearing potential, have a negative urine pregnancy test at the
             baseline visit and prepare to abstain from sexual intercourse or use a reliable
             method of contraception during the study (e.g., condom, IUD, oral, injected,
             transdermal or implanted hormonal contraceptives). Patients on hormonal
             contraceptives must have been on the same method/type for at least 28 days prior to
             the start of the study and remain on the same throughout the study.

          4. The presence of infection confirmed by a positive bacterial culture for the presence
             of Pseudomonas aeruginosa or Staphylococcus aureus. As the results of the bacterial
             culture will not be immediately known, patients who meet all the other
             inclusion/exclusion criteria may be enrolled in the study pending the results of the
             bacterial culture.

          5. Clinical signs and symptoms consistent with bacterial otitis externa as defined by a
             combined Total Symptom Score (TSS) of at least 6 with a score of least 2 for otalgia
             using the following scale 0=none, 1=mild, 2=moderate, 3=severe.

        Exclusion Criteria:

          1. Females who are pregnant, breast feeding, or anticipate becoming pregnant during the
             study.

          2. Signs and symptoms of otitis externa for longer than 21 days prior to being screened
             for inclusion in the study.

          3. Previous episode of otitis externa within the previous 6 months or more than 2
             episodes within the previous 12 months.

          4. Been provided any therapeutic drug treatment for current episode of otitis externa.

          5. Known history of, or ear exam reveals tympanic membrane perforation or damage for any
             reason.

          6. Current or previous history of any otologic surgery including insertion/removal of
             tympanostomy tubes in infected ear(s).

          7. Clinical diagnosis that suggests current signs or symptoms are not caused by acute
             bacterial otitis externa e.g. chronic suppurative otitis externa, acute otitis media

          8. Clinical diagnosis of malignant otitis externa

          9. Mastoid cavities, stenosis, exostosis or tumors of either ear or other noninfectious
             diseases of either ear.

         10. Suspected concurrent fungal or viral infection (e.g. herpes simplex) of either ear.

         11. Dermatitis of the infected ear such as psoriasis or seborrhea that would complicate
             evaluations.

         12. Significant underlying disease such as diabetes, HIV or other immunocompromised
             conditions or receiving therapy that may cause patient to be immunocompromised.

         13. Significant history or current evidence of chronic infectious disease, system
             disorder, organ disorder or other medical condition that in the Investigator's
             opinion would place the study patient at undue risk by participation or could
             jeopardize the integrity of the study evaluations.

         14. Investigator believes that severity of infection is such that systemic antibiotics
             would be the preferred treatment option.

         15. Use of any systemic antibacterial products or topical antibacterial products in the
             ear(s) within 28 days of screening for the study.

         16. Use of any systemic anti-inflammatory products or topical anti-inflammatory products
             in the ear(s) (such as corticosteroids and NSAIDs) within 7 days of screening for the
             study.

         17. Use of any topical or otic medication in the affected ear within 2 weeks prior to
             screening.

         18. Use of any astringents such as vinegar, alcohol or medicated cleansing or swabbing of
             the ear within 48 hours of the baseline bacterial culture swab.

         19. Any known hypersensitivity to ciprofloxacin or other carboxyquinolone derivatives,
             dexamethasone or corticosteroids or other ingredients of the formulation.

         20. Receipt of any drug or device as part of a research study within 30 days prior to
             dosing.

         21. Previous participation in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandra S Vattikonda, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Par Pharamceutical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail Gongas</last_name>
    <phone>412-363-3300</phone>
    <phone_ext>x522</phone_ext>
    <email>gdgongas@novumprs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>James Donivan Gordon, MD</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Wilson</last_name>
      <phone>520-623-2092</phone>
    </contact>
    <investigator>
      <last_name>James Donivan Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nea Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Hammett</last_name>
      <phone>870-934-1006</phone>
    </contact>
    <investigator>
      <last_name>John Dow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Applied Reserch Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorrie Brickell</last_name>
      <phone>501-954-7822</phone>
    </contact>
    <investigator>
      <last_name>Steve Simpson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Champlin, MD</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Mellor</last_name>
      <phone>916-966-7452</phone>
    </contact>
    <investigator>
      <last_name>John Champlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aliance Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noell Tabirara</last_name>
      <phone>562-366-2554</phone>
    </contact>
    <investigator>
      <last_name>Chok Won, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT of South Florida</name>
      <address>
        <city>Boyton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virgilio Lopez</last_name>
      <phone>561-737-8584</phone>
    </contact>
    <investigator>
      <last_name>Joshua Light, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research Inc</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Cardinas</last_name>
      <phone>813-948-7550</phone>
    </contact>
    <investigator>
      <last_name>Bill Fulk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jorge Diaz, MD</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nubia Conception</last_name>
      <phone>305-441-6611</phone>
    </contact>
    <investigator>
      <last_name>Jorge Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical Consulting Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Becerra</last_name>
      <phone>305-649-0492</phone>
    </contact>
    <investigator>
      <last_name>Jalal Taslimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Peralta</last_name>
      <phone>305-424-7420</phone>
    </contact>
    <investigator>
      <last_name>Idalia Acosta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ormond Medical Arts Pharmaceutical Research Center</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Marsden</last_name>
      <phone>386-236-2456</phone>
    </contact>
    <investigator>
      <last_name>James Shoemaker, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winter Park Clinical Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Williams</last_name>
      <phone>407-678-5554</phone>
    </contact>
    <investigator>
      <last_name>Gregory Samano, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Integrity, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabetha Maden</last_name>
      <phone>270-691-1827</phone>
    </contact>
    <investigator>
      <last_name>Kishor Vora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pioneer Clinical Research</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Goolsby</last_name>
      <phone>402-291-8704</phone>
    </contact>
    <investigator>
      <last_name>Darin Gregory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarrod Underwood</last_name>
      <phone>919-783-4895</phone>
    </contact>
    <investigator>
      <last_name>Brian Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Dillard</last_name>
      <phone>704-647-9913</phone>
    </contact>
    <investigator>
      <last_name>Willard Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Julia Mullen, MD</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Broadnax</last_name>
      <phone>513-381-4100</phone>
    </contact>
    <investigator>
      <last_name>Julie Mullen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Medical Research PC</name>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <zip>97520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Harding</last_name>
      <phone>541-552-1111</phone>
    </contact>
    <investigator>
      <last_name>John Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cyn3rgy</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curt Heiting</last_name>
      <phone>503-907-2179</phone>
    </contact>
    <investigator>
      <last_name>Frank Calcagno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peak Research LLC</name>
      <address>
        <city>Upper St. Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Miller</last_name>
      <phone>412-595-7681</phone>
    </contact>
    <investigator>
      <last_name>James Moretti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Ansley, MD</name>
      <address>
        <city>Orangeburgh</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Ansley</last_name>
      <phone>803-536-5511</phone>
    </contact>
    <investigator>
      <last_name>John Ansley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg and Geer ENT</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Gossett</last_name>
      <phone>864-582-2900</phone>
    </contact>
    <investigator>
      <last_name>Henry Butehorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monica Davis, MD</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Lawhun</last_name>
      <phone>615-457-2352</phone>
    </contact>
    <investigator>
      <last_name>Monica Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gilbert Ledesma, MD</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megann Eiler-Prater</last_name>
      <phone>817-509-0084</phone>
    </contact>
    <investigator>
      <last_name>Gilbert Ledesma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Service</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bula</last_name>
      <phone>281-738-2642</phone>
    </contact>
    <investigator>
      <last_name>Oscar DeValle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>R-D Clinical Research</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Morton</last_name>
      <phone>979-297-3535</phone>
    </contact>
    <investigator>
      <last_name>Brian Feaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Education and Research Foundation Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Foster</last_name>
      <phone>434-847-8400</phone>
    </contact>
    <investigator>
      <last_name>Timothy Courville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO The Clinical Research Group</name>
      <address>
        <city>Canovanas</city>
        <zip>00729</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salima Dhanji</last_name>
      <phone>972-390-9853</phone>
    </contact>
    <investigator>
      <last_name>Norma Severino-Pecheco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico Guayama</name>
      <address>
        <city>Levittown</city>
        <zip>00949</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salima Dhanji</last_name>
      <phone>972-390-9853</phone>
    </contact>
    <investigator>
      <last_name>Yolanda Quinones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO The Clinical Research Group</name>
      <address>
        <city>Naranjito</city>
        <zip>00719</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salima Dhanji</last_name>
      <phone>972-390-9853</phone>
    </contact>
    <investigator>
      <last_name>Limarys Cruz Ortiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO The Clinical Research Group</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salima Dhanji</last_name>
      <phone>972-390-9853</phone>
    </contact>
    <investigator>
      <last_name>Ramul Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO The Clinical Resarch Group</name>
      <address>
        <city>Santa Isabel</city>
        <zip>00757</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salima Dhanji</last_name>
      <phone>972-390-9853</phone>
    </contact>
    <investigator>
      <last_name>Samuel Borrero Dejesus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 25, 2013</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis Externa</mesh_term>
    <mesh_term>Otitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
